PhD 

Professor - Department of Microbiology and Immunology 

Lena Öhman's research group is successfully focusing on describing gut microbiota, immune profile and the link to disease profile and therapy outcome in patients with inflammatory bowel disease (IBD) and patients with with irritable bowel syndrome (IBS). 

Prof. Öhman, with a distinguished career spanning from her PhD thesis defense in 2002 to her recent appointment as a full professor in 2020, has made significant strides in the field of microbiota research. A Pioneering Career Prof. Öhman’s journey in academia has been nothing short of extraordinary. After completing her doctoral studies, she embarked on a journey that took her to Danone Research and INRAE Île-de-France - Jouy-en-Josas for a research sabbatical in 2012-2013. Her diverse experiences have enriched her perspective, leading to innovative insights in her field. Unraveling Complexities in Gastrointestinal Disorders During her captivating presentation at Targeting Microbiota 2023, Prof. Öhman delved deep into the intricate challenges posed by gastrointestinal disorders. Her talk not only explored the nuances of monitoring and diagnosing these diseases but also illuminated the mechanisms that underlie their initiation and persistence. Of particular significance was her examination of the potential of fecal gut microbiota and metabolite signatures as promising biomarkers for gastrointestinal disorders. Dedicated Research Group Prof. Öhman’s commitment to advancing our knowledge of gastrointestinal diseases extends beyond the lecture hall. She leads a dynamic research group at the University of Gothenburg, tirelessly working to uncover how gut microbiota and immune activity influence the course of these disorders. Their collective mission is to identify microbiotic and immunological indicators that can guide therapy decisions and improve outcomes for patients. Prof, Öhman shared with the International Society of Microbiota: "We aim to continue to explore the potential of intestinal microbiota and metabolome as diagnostic biomarkers for inflammatory bowel disease, but also for colitis-associated colon cancer. Furthermore, we aim investigate the underlying principles of how commensal microbiota govern intestinal T cells and B cells in inflammatory bowel disease". Innovative Approaches In addition to discussing biomarkers, Prof. Öhman shared insights into the prospective use of in vitro cell culture models as powerful tools for studying the mechanisms of disease. Her comprehensive presentation illuminated the current state of research in this field, inspiring fellow researchers and clinicians alike. We extend our heartfelt congratulations to Prof. Lena Öhman for her outstanding achievements and dedication to advancing our understanding of gastrointestinal disorders and the role of gut microbiota. Her pioneering contributions in the field are truly commendable, and we eagerly anticipate further advancements in this critical area of research.